^
Association details:
| Biomarker: | ATRX mutation |
|---|---|
| Cancer: | Leiomyosarcoma |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma
Published date:
05/15/2020
Excerpt:
In ERI-treated patients, the presence of ATRX mutations was more frequently observed in patients progressing on ERI (7/20 in patients with PD vs . 1/20 in group with disease control; p=0.0435) . The presence of ATRX mutation had a negative impact on both PFS and OS . TP53 mutations were associated with longer PFS, and these mutations were more frequently observed in patients achieving disease control, although this was not statistically significant (11/20 vs . 5/20).
